Introduction
Polymorphonuclear and mononuclear phagocytes function in host defense against infections and are capable of recognizing, ingesting, and destroying foreign materials and organisms. Pluripotent hematopoietic stem cells in fetal liver or in adult marrow give rise to granulocyte/macrophage progenitors (GMPs), characterized by expression of CD34 and Fcg Receptor(II/III) Traver et al., 2001) . These progenitors in turn give rise to granulocyte-, monocyte-, and granulocyte/monocyte-colony forming units (CFU-G, CFU-M, and CFU-GM). Granulocyte-Colony Stimulating Factor (G-CSF) enables the formation of CFU-G in methylcellulose cultures, MacrophageColony Stimulating Factor (M-CSF, CSF-1) enables the growth of CFU-M, and Granulocyte/MacrophageColony Stimulating Factor (GM-CSF) or Interleukin-3 (IL-3) enable the proliferation of CFU-G, CFU-M, and CFU-GM. In addition to these features of normal cells, the ®nding that a common subset of acute myeloid leukemia has both a granulocytic and monocytic cellular component further underscores the close developmental relationship of neutrophils and monocytes. Fetal liver and adult marrow also contain progenitors capable of producing B-lymphoid and macrophage cells in single colonies, re¯ecting both the plasticity of pluripotent stem cell commitment and the relatedness of these lineages (Lacaud et al., 1998; Montecino-Rodriguez et al., 2001; Traver et al., 2001 ). Monocyte progenitors not only develop into macrophages but are also capable of osteoclast dierentiation (Roodman, 1996) , and GMPs share with common lymphoid progenitors (CLPs) the capacity to generate myeloid dendritic cells (Manz et al., 2001) .
Neutrophil maturation proceeds from the myeloblast to the promyelocyte, when primary granules become apparent, to the myelocyte, when cell division ceases and secondary or speci®c granules begin to appear, to the metamyelocyte, band, and ®nally the neutrophil, which has a three-lobed nucleus and tertiary granules. Early markers of granulopoiesis include the G-CSF Receptor, the CD33 and CD13 surface markers, and primary granule components, such as myeloperoxidase (MPO), neutrophil elastase (NE), myeloblastin (MBN), lysozyme and avian mim-1. Oxidation system components, such as the gp91-phox cytochrome heavy chain, are expressed from the myelocyte stage onward and later markers of neutrophil development include secondary granule components, such as lactoferrin (LF) and neutrophil gelatinase (NG) , and the Gr-1 surface marker.
Monopoiesis proceeds from the monoblast to the circulating monocyte, which matures without proliferation to the tissue macrophage. Early markers of this lineage include the M-CSF Receptor, lysozyme, and the Fcg Receptor(II/III), and latter markers include gp91-phox, and several surface proteins: Macrosialin, scavenger receptor (SR), F4/80, CD14, CD11b, and CD18. Fcg Receptor(II/III) is also expressed on myeloid progenitors (Carlsson et al., 1995) ; the CD11b:CD18 integrin is also expressed on neutrophils, B-lymphocytes, and some T-cell subsets ; and CD14 is also expressed in hepatocytes . Phagocytic capacity is an additional hallmark of maturing monocytes.
Receptor signaling
We have recently reviewed how G-CSF Receptor signals might modulate granulopoiesis . Redundancy of receptor signaling is evident from the ®nding that G-CSF (7/7), G-CSF; GM-CSF (7/7; 7/7); G-CSFR (7/7), or G-CSFR; IL-6 Receptor (7/7; 7/7) mice have only about a twofold reduction in marrow neutrophils (Lieschke et al., 1994; Liu et al., 1996a Liu et al., , 1997 Seymour et al., 1997) . Bcl-2 did not replace G-CSF receptor signals during 32D cl3 maturation-MPO and Cathepsin G induction did not occur, but nuclear morphologic changes were observed (Rodel and Link, 1996) . Thus, G-CSF receptor signals provide more than a survival function in this setting. Similarly, G-CSF receptor signals cooperated with exogenous C/EBPa to allow induction of MPO and NE in Ba/F3 lymphoid cells and were required for induction of C/EBPe in 32D cl3 cells (Wang et al., 2001; Nakajima and Ihle, 2001) . Also, introduction of exogenous GM-CSF or IL-2 receptors allows CLPs to be redirected to the granulocyte and monocyte lineages (Kondo et al., 2000) .
M-CSFR signaling has also recently been reviewed (Bourette and Rohrschneider, 2000) . Transgenic expression of bcl-2 in monocytes enabled M-CSF (7/7) mice to develop macrophages (Lagasse and Weissman, 1997) . While this ®nding precludes an absolute requirement for M-CSF Receptor signals in macrophage development, redundant signals available from a subset of other cytokine receptors may be necessary. The ability of phorbol esters to induce monocytic dierentiation of hematopoietic cell lines via activation of protein kinase Ca (PKCa) or PKCd suggests that this signaling pathway is important in normal monopoiesis (Mischak et al., 1993) . Overall, with possible notable exceptions, signals eminating from cytokine receptors appear to modulate but not determine myeloid dierentiation.
Regulation of gene expression
Dierentiation is de®ned by gene expression patterns, and so regulatory factors must act either directly or indirectly to induce the transcription of lineage markers. Therefore, studies investigating the regulation of granulocyte-and monocyte-speci®c genes, as summarized in Table 1 , will be reviewed initially. The subsequent sections will then describe additional insights gained from characterizing transcription factor expression patterns, the phenotypes of knockout mice, and the eects of factor over-expression.
The promoter of the avian mim-1 promoter is activated cooperatively by C/EBPs and c-Myb in immature granulocytic cells (Ness et al., 1993) . This section will not refer to individual C/EBPs, as C/EBP family members bind a common DNA motif and often activate reporter constructs similarly in transient assays. The MPO promoter region is activated cooperatively by CBF and c-Myb (Suzow and Friedman, 1993; Nuchprayoon et al., 1994; Britos-Bray and Friedman, 1997) , and its distal enhancer is regulated by C/EBPs and PU.1 (Ford et al., 1996) . The NE promoter is regulated cooperatively by C/EBPs, PU.1, and c-Myb; the murine but not the human NE promoter is activated weakly by CBF; GABP can substitute for PU.1 to cooperatively active the NE promoter; and a 76 kb NE enhancer is activated by Sp1 and an Ets family member other than PU.1 (Nuchprayoon et al., 1994; 1997 , 1999 Oelgeschlager et al., 1996) . MBN and azurocidin are serine proteases highly related to NE. Their promoters contain sequences elements homologous to the NE elements which bind C/EBPs, PU.1, and c-Myb (Friedman, 1996a) , and indeed these proteins regulate the MBN promoter (Lutz et al., 2001) . The promoters of both the G-CSF and GM ± CSF receptor genes are activated by C/EBPs and PU.1 (Hohaus et al., 1995; Smith et al., 1996) . The CD13 gene is activated directly by c-Myb and Ets-1 or Ets-2, and c-Maf indirectly inhibits the transcription of this gene by complexing with c-Myb in immature but not maturing granulocyte precursors (Shapiro, 1995; Hegde et al., 1998) . The avian lysozyme gene 72.7 kb enhancer is regulated by C/ EBPs and PU.1, and its 76.1 kb enhancer is activated by C/EBPs (Ahne and Stratling, 1994; Goethe and Loc, 1994; Faust et al., 1999) . Consistent with these results, we recently found that activation of exogenous C/EBPa-ER with estradiol in the murine 32D cl3 myeloblast cell line rapidly induces lysozyme RNA expression in the presence of cycloheximide but not actinomycin D (Wang and Friedman, 2002) . Finally, the c-fes tyrosine kinase promoter region is regulated by PU.1 and Sp1 in immature granulocytic and monocytic cells (Heydemann et al., 1996) . In maturing neutrophils, the gp91-phox promoter region is activated by the PU.1:ICSBP dimer and is repressed by both CDP and HoxA10 ± the levels of the latter factors decrease during terminal neutrophil and monocyte dierentiation (Skalnik et al., 1991; Eklund and Kakar, 1999; Eklund et al., 2000) . The LF promoter is activated by C/EBPs and Sp1 and is repressed by CDP (Khanna-Gupta et al., 1997 . CDP represses both the gp91-phox and LF promoters via interaction with sites upstream of activator binding sites (Luo and Skalnik, 1996; Khanna-Gupta et al., 1997) , and CDP also represses the gp91-phox promoter via a site 790 which overlaps an activator-binding site (Catt et al., 1999) . HoxA10 interacts with an AT-rich element located just upstream of the 5'-CCAAT sequence at 790, the binding site for CDP, and so like CDP may repress gp91-phox transcription, in part, via competition with activators (Eklund et al., 2000) . The MPO promoter contains a potent repressor element active in 32D cl3 cells which has been mapped to a 28 bp segment which includes a 5'-GAAATC sequence conserved in the homologous region of the human MPO gene (Suzow and Friedman, 1993) . Perhaps this element binds CDP or HoxA10, repressors thought to be more active in immature than mature granulocytes.
In immature monocytic cells, the M-CSF Receptor promoter is activated synergistically by C/EBP, PU.1, and CBF (Zhang et al., 1994a (Zhang et al., ,b, 1996a Petrovick et al., 1998) , and c-Jun activates the M-CSF receptor gene indirectly, via its ability to interact with PU.1 (Bassuk and Leiden, 1995; Behre et al., 1999a) . In cells dierentiating into macrophages, the macrosialin and scavenger receptor promoters are activated cooperatively by PU.1 and c-Jun, via binding sites separated by 33 or 135 bps, respectively (Moulton et al., 1994; . The CD14 promoter is activated by C/EBP and Sp1 (Zhang et al., 1994c; Pan et al., 1999) . And ®nally, PU.1 and Sp1 activate both the CD11b and CD18 promoters; optimal transcription of the latter gene also requires GABP, which like PU.1 is a member of the Ets family of transcription factors Chen et al., 1993; Rosmarin et al., 1995a Rosmarin et al., ,b, 1998 .
From these studies, C/EBPs and PU.1 emerge as the most consistent regulators of genes expressed in granulocytic and immature monocytic cells. PU.1 also activates most genes expressed in mature monocytic cells, c-Myb and CBF contribute to the activation of several genes in proliferating cells, and Sp1 activates several promoters in neutrophils and mature monocytes. The next section will describe additional evidence which con®rms the importance of these factors, as well as evidence implicating additional transcription factors, in the regulation of granulocyte and monocyte development. The subsequent section will then address the question of how these factors orchestrate the myeloid developmental program.
Transcription factors

C/EBPs
The C/EBPs homo-and hetero-dimerize via their Cterminal leucine zipper domains and bind DNA as dimers via the adjacent basic regions . The C/EBP consensus binding site is 5'-T(T/ G)NNGNAA(T/G)-3'. C/EBPa, C/EBPb, and C/EBPd have N-terminal trans-activation domains, and translation initiation from internal methionines produces truncated, dominant-inhibitory polypeptides which retain the bZIP domain McKnight, 1990; Descombes and Schibler, 1991; Calkhoven et al., 2000) . C/EBPe has both a trans-activation and a trans-repression domain (Williamson et al., 1998) , and C/EBPg and CHOP are dominant-inhibitory due to their ability to dimerize with other C/EBPs and their lack of intact basic regions (Habener and Ron, 1992; Cooper et al., 1995) . Trans-activation by C/EBPa may be regulated via Rasinduced phosphorylation of serine 248 (Behre et al., 1999b) .
Within hematopoiesis, full-length C/EBPa, C/EBPb, and C/EBPd are predominantly expressed in the granulocyte, monocyte, and eosinophil lineages (Scott et al., 1992; Muller et al., 1995; Radomska et al., 1998) . C/EBPa is the isoform most prominently detected in immature granulocytes (Scott et al., 1992; Hohaus et al., 1995) , whereas C/EBPe is found in later-stage granulocytes and in T-cells (Antonson et al., 1996) . CHOP is only detected in granulocytic cells subjected to stress, such as DNA-damage (Friedman, 1996b) , and C/EBPg expression in this lineage is not well characterized.
C/EBPa (7/7) mice lack neutrophils and eosinophils, but retain monocytes, lymphocytes, erythroid cells, and immature myeloblasts . Fetal liver cells from these mice lack GranulocyteColony Stimulating Factor (G-CSF) Receptor RNA, consistent with the ability of C/EBPa to trans-activate the G-CSF Receptor promoter (Smith et al., 1996) . Induction of G-CSF or IL-6 Receptor cDNAs into C/ EBPa (7/7) fetal liver cells restores their ability to generate neutrophils in vitro in response to G-CSF or IL-6 . C/EBPb (7/7) mice retain all of the hematopoietic lineages, and hematopoietic defects in mice lacking C/EBPd or both C/EBPb and C/EBPd were not severe (Screpanti et al., 1995; Tanaka et al., 1995 Tanaka et al., , 1997 . C/EBPe (7/7) mice also retain neutrophils, although they lack secondary granules (Yamanaka et al., 1997; Chumakov et al., 1997; Lekstrom-Himes et al., 1999; Gombart et al., 2001) .
Expression of C/EBPa in U937 cells led to the development of neutrophilic cells after 2 weeks, with expression of the mRNAs encoding G-CSF Receptor, lactoferrin, and neutrophil collagenase (Radomska et al., 1998) . Introduction of C/EBPa into avian multipotent progenitors also led to expression of myeloid markers (Nerlov et al., 1998) . Similarly, estradiolmediated activation of C/EBPa-ER in 32D cl3 cells, a factor-dependent, diploid cell line, induced neutrophils within 4 days, with induction of MPO, lactoferrin, and G-CSF Receptor RNAs (Wang et al., 1999) . MPO RNA was induced within 8 h of C/EBPa-ER activation, but not in the presence of cycloheximide, indicating the need for an additional C/EBP-dependent factor. A likely candidate is PU.1, as C/EBPa-ER induced PU.1 RNA within 4 h, even in the presence of cycloheximide. C/EBPa-ER also rapidly induced the lysozyme and C/EBPe RNAs in the presence of cycloheximide, but not actinomycin D, suggesting direct regulation of the murine lysozyme and C/EBPe genes by C/EBPs (Wang and Friedman, 2002) . The signi®cance of C/EBPa regulation of PU.1 and C/EBPe RNA expression will be discussed further below. As C/ EBPa is expressed in non-hematopoietic cells, it is interesting to speculate that early regulators of hematopoiesis, such as c-Myb, CBF, or GATA-2, prime the PU.1 and C/EBPe genes for activation by C/ EBPa. The ability of CEBPa to activate its own promoter may also assist in committing progenitors to the myeloid lineages (Christy et al., 1993) .
The presence of several C/EBPs in myeloid cells suggests that family members might compensate in vivo for the lack of a single isoform, just as GATA family members partially compensate for the lack of GATA-1 (Kulessa et al., 1995; Tsai et al., 1998) . Indeed, as with C/EBPa, C/EBPb, C/EBPd, or C/EBPe can induce granulocytic dierentiation in myeloblastic cell lines (Park et al., 1999; Nakajima and Ihle, 2001; Wang and Friedman, 2002) , and C/EBPa, C/EBPb, or C/EBPd induced monocytic genes in P388 lymphoblasts (Hu et al., 1998) . Redundancy is also evident from the ability of C/EBPb to compensate for the loss of C/EBPa in hepatocytes and granulocytes in vivo (Chen et al., 2000; Jones et al., 2002) . In addition, compensatory eects may account for the ability of immortalized C/EBPa (7/7) progenitors to express high levels of G-CSF Receptor in vitro, even though they could not respond to G-CSF in vivo (Collins et al., 2001) . Global inhibition of C/EBP-regulated genes can be achieved by expression of KRAB-C/EBPa-ER (KaER), in which the C/EBPa DNA-binding domain is linked to both a KRAB trans-repression domain and the Estrogen Receptor ligand-binding domain. In 32D cl3 cells, KaER inhibits granulocytic dierentiation despite the presence of exogenous G-CSF receptor (Wang and Friedman, 2002) . And in marrow cells, KaER inhibits the formation of CFU-G, CFU-M, and CFU-GM in multiple cytokines, without aecting BFU-E production (Wang and Friedman, 2002 ).
In addition to regulating dierentiation in several lineages, C/EBPa regulates proliferation directly. Decreased expression in proliferating versus quiescent hepatocytes and its ability to slow 3T3-L1 preadipocyte proliferation provided the initial evidence that C/EBPs aect cell cycle progression Umek et al., 1991) . Both C/EBPaWT-ER and KaER inhibit progression from G1 to S phase in 32D cl3 cells (Wang et al., 1999; Friedman and Wang, 2000) . These proteins may inhibit the G1/S transition via interaction with E2F (Timchenko et al., 1999; Slomiany et al., 2000; Johansen et al., 2001) . A KaER variant with a defective leucine zipper domain does not slow 32D cl3 proliferation (Wang and Friedman, 2002) . Perhaps C/ EBPa dimers are required for interaction with E2F or with another protein associated with the E2F complexes, or perhaps C/EBPa monomers interact with one of these proteins via its leucine zipper. In fact, E2F contains a leucine zipper, as noted (Slomiany et al., 2000) . C/EBPe also slows 32D cl3 proliferation (Nakajima and Ihle, 2001 ). Inhibition of proliferation by C/EBPa or C/EBPe may contribute to granulopoiesis, as maneuvers which stimulate proliferation, such as over-expression of c-Myb or cdk4, prevent induction of late markers (Bies et al., 1995; Lou et al., 2000) . Similarly, expression of p21 WAF1/CIP1 or p27 Kip1 in U937 cells induces monocytic markers . On the other hand, induction of p27
Kip1 with mimosine induced Lysozyme RNA but inhibited MPO RNA, an earlier dierentiation marker, in 32D cl3 cells (Q Wang and AD Friedman, unpublished) . The potential roles of p53 and hypo-phosphorylated Rb in terminal myeloid dierentiation will be discussed below.
PU.1 and interacting proteins, ICSBP, c-Jun, and GATA-1 PU.1 binds DNA as a monomer, via its C-terminal Ets domain, to the consensus site 5'-AAAG(A/C/ G)GGAAG-3' (Klemsz et al., 1990) . The DNA-binding domain of PU.1 and its N-terminal, glutamine-rich trans-activating domain were both required to rescue myelopoiesis in PU.1 (7/7) ES cells, whereas its acidic trans-activating domain was dispensable (Fisher et al., 1998) .
Phosphorylation of serine 148 in PU.1 allows interaction with Pip, also known as Interferon response factor-4 (IRF-4), an essential co-factor in B cells (Eisenbeis et al., 1995) . Pip or Interferon consensus sequence binding protein (ICSBP, can interact with PU.1 in monocytic cells, enabling trans-activation via a hybrid DNA-element binding element (Meraro et al., 1999; Marecki et al., 2001) . However, an essential role for Pip or ICSBP interaction for PU.1 activity in myeloid cells has not been established. Notably, ICSBP (7/7) mice have reduced macrophages and increased granulocytic cells, and introduction of ICSBP into a cell line derived from the knockout mice increased monocytic markers at the expense of granulocytic markers (Holtschke et al., 1996; Tamura et al., 2000) .
As discussed, c-Jun also cooperates with PU.1 to regulate several monocytic genes, either via adjacent cis DNA elements or via direct interaction. Notably, cJun, JunB, and JunD levels increase during monocytic dierentiation (Lord et al., 1993) , and exogenous c-Fos or c-Jun induced partial monocytic dierentiation in M1, U937, or WEHI-B D+ cells and increased the responsiveness of U937 cells to phorbol esters (Lord et al., 1993; Szabo et al., 1994; Li et al., 1994) . Phorbol esters, an agent which stimulates the monocytic dierentiation of several myeloid cell lines, directly induces the c-Jun promoter via binding sites for cJun:ATF-2 dimers (van Damm et al., 1993) . Phorbol esters or other stimuli active N-terminal Jun Kinases (JNKs), which in turn phosphorylate c-Jun and ATF-2, increasing their trans-activation potency (Arias et al., 1994) . Phorbol esters also induce the JunB promoter (de Groot et al., 1991) . JunB (7/7) mice in which JunB expression has been rescued in tissues other than marrow retain normal monocyte numbers but develop granulocytic hyperplasia . c-Jun (7/7) fetal liver cells reconstitute hematopoiesis in syngeneic recipients, indicating that, as with JunB, cJun is not required for myeloid development (Eferl et al., 1999) . These ®ndings may re¯ect both compensatory eects among Jun family members during monocytic dierentiation and a speci®c role for JunB as an inhibitor of proliferation in the granulocyte lineage. c-Jun accelerates cell proliferation in ®bro-blasts and hepatoblasts, suggesting that c-Jun and JunB are mutually antagonistic in this regard in myeloid cells . In fact, JunB antagonizes the trans-activation potential of c-Jun (Chiu et al., 1989; Schutte et al., 1989) .
PU.1 also interacts with GATA-1 and inhibits its ability to activate erythroid genes, thereby likely contributing to lineage-speci®c expression in myeloid cells (Rekhtman et al., 1999; Zhang et al., 2000) . Similarly, C/EBPb, and potentially other C/EBPs, reduces FOG but not GATA-1 RNA expression, potentially directing CMPs to the GMP or to an eosinophil progenitor (Querfurth et al., 2000) .
PU.1 is expressed in B lymphoid, granulocytic, and monocytic cells (Klemsz et al., 1990; Chen et al., 1995a) . PU.1 levels increase during granulocytic and monocytic dierentiation (Cheng et al., 1996) . PU.1 (7/7) mice lack B lymphoid cells and monocytes and have greatly reduced neutrophil development McKercher et al., 1996) . Introduction of the G-CSF Receptor or M-CSF Receptor into PU.1 (7/ 7) marrow cells did not enable generation of monocytes or neutrophils Anderson et al., 1999) . Just as C/EBPa (7/7) progenitors gain the ability to generate neutrophils when cultured in vitro, PU.1 (7/7) progenitors express myeloperoxidase in IL-3 and G-CSF and express markers of immature monocytes when cultured in the combination of IL-3, SCF, GM-CSF, and M-CSF Henkel et al., 1999) . Similarly, PU.1 (7/7) ES cells express several early myeloid RNAs (Olson et al., 1995) . Perhaps this apparent relaxed`stringency' re¯ects redundancy among Ets family members which is more eective in vitro. For example, GABP can substitute for PU.1 to activate the NE promoter in 32D cl3 cells (Nuchprayoon et al., 1997) .
Activation of exogenous PU.1-ER in 32D cl3 cells is not sucient to induce terminal granulopoiesis, although increased MPO RNA is detected (Wang et al., 1999) . Similarly, stable expression of PU.1 in 32D cl3 cells is of no consequence in IL-3, but accelerates their dierentiation in G-CSF (Bellon et al., 1998) . In contrast, over-expression of PU.1 in normal Blymphoid progenitors leads to the outgrowth of macrophages at high levels of PU.1 expression and to the generation of B-cells at lower levels of PU.1 (DeKoter and Singh, 2000) . The ability of PU.1 to activate its own promoter may play a role in maintaining high levels of PU.1 expression in myeloid cells (Chen et al., 1995b) .
Core binding factors (CBFs)
The role of CBFs in normal hematopoiesis and in leukemia was recently reviewed (Friedman, 1999) . The CBFs are a family of heterodimeric proteins containing a common CBFb subunit and one of three CBFa subunits, CBFa1, CBFa2 (commonly referred to as AML1), and CBFa3 (Bae et al., 1993; Wang et al., 1993; Ogawa et al., 1993a , Levanon et al., 1994 . CBFs bind the consensus site, 5'-PuACCPuCA-3' via their Nterminal Runt homology domains (Ogawa et al., 1993a; Meyers et al., 1993) . CBFb does not contact DNA, but interacts with the CBFa subunits via their Runt domains and increases their anity for DNA (Wang et al., 1993; Ogawa et al., 1993b) . AML1 can also interact with DNA indirectly, via interaction with a subset of Ets family members, including MEF, Ets-1, and PU.1, and via interaction with C/EBPa (Westendorf et al., 1998; Mao et al., 1999) .
CBFa2 (AML1) expression is largely restricted to myeloid and lymphoid cells, including CD34+ precursors, in adult mice, whereas CBFa1 is most highly expressed in osteoblasts, and CBFb is widely expressed (Satake et al., 1992; Wang et al., 1993; Erickson et al., 1996; Corsetti and Calabi, 1997; Ducy et al., 1997) . AML1 (7/7) and CBFb (7/7) mice die as embryos without developing de®nitive hematopoiesis, whereas CBFa1 (7/7) mice have normal blood formation but do not develop calci®ed bones (Okuda et al., 1996; Wang et al., 1996a,b; Sasaki et al., 1996; Niki et al., 1997; Komori et al., 1997) . Adult mice chimeric for CBFb-SMMHC, a dominant-inhibitor of CBFs, develop erythroid but not myeloid or lymphoid cells expressing CBFb-SMMHC, consistent with a speci®c role for CBFs in the maturation of these lineages in adult marrow (Castilla et al., 1999) .
In addition to activating lineage-speci®c markers such as MPO and the M-CSF receptor, CBFs stimulate the G1 to S transition in myeloid and lymphoid cell lines (Cao et al., 1997 (Cao et al., , 1998 Lou et al., 2000; Strom et al., 2000) . Exposure of 32D cl3 cells to mimosine, which inhibits G1 progression via induction of p27 Kip1 , prevented G-CSF-mediated induction of MPO, an early granulocytic marker, but accelerated induction of two later markers, LF and Lysozyme (Q Wang and AD Friedman, unpublished) . This ®nding suggests that proliferation is a prerequisite for the activation of proteins such as CBF and c-Myb expressed in immature cells and meant to serve a dual role by simultaneously stimulating proliferation and dierentiation.
c-Myb
c-Myb binds the consensus DNA site 5'-(C/T)AAC(G/ T)-3' (Biedenkapp et al., 1988) . The 52 amino acid R2 and R3 segments located near the N-terminus of cMyb contain tryptophans every 18 ± 19 residues which are part of the hydrophobic core of a helix ± turn ± helix structure (Ogata et al., 1992) . c-Myb has a central trans-activating domain, and its C-terminus has an EVES motif which interferes with DNAbinding by the N-terminus (Weston and Bishop, 1989; Dash et al., 1999) . The C-terminal region of cMyb also contains a leucine zipper, which has been shown to interact with a protein termed p160 (Tavner et al., 1998) . c-Myb is expressed in immature myeloid, lymphoid, and erythroid cells, and c-Myb (7/7) mice lack each of these lineages (Sheiness and Gardinier, 1984; Mucenski et al., 1991) . Expression of exogenous c-Myb in 32D cl3 cells allowed G-CSF induction of MPO but prevented growth arrest and associated induction of late markers such as LF (Bies et al., 1995) . A-Myb and B-Myb are highly homologous to c-Myb within its DNA-binding domain and bind the identical consensus sequence (Trauth et al., 1994) . AMyb is expressed in several tissues, including a subset of B cells, while B-Myb is expressed widely in proliferating cells and may stimulate cell cycle progression (Golay et al., 1991; Reiss et al., 1991; Trauth et al., 1994) .
MafB and c-Maf
MafB and c-Maf are members of a family of basic region-leucine zipper DNA-binding proteins. Mafs bind and activate transcription weakly as dimers via a 13 bp palindrome, 5'-TGCTGACTCAGCA-3', which contains a central AP-1 site, 5'-TGACTCA-3' (Kataoka et al., 1994a,b; Kerppola and Curran, 1994) . Mafs can also form heterodimers with Fos or Jun family members which bind modi®ed consensus sites (Kataoka et al., 1996) . Mafs interact with another bZIP protein, NF-E2, in erythroid cells, enabling induction of globin and other erythroid-speci®c genes (Andrews et al., 1993) . MafB is expressed in myeloid cells, including marrow macrophages, but not in erythroid cells, and it inhibits erythroid gene expression via direct interaction with Ets-1 (Sieweke et al., 1996) . When avian progenitors were transformed by a Myb-Ets fusion protein in the presence of exogenous MafB, an increased number of myeloid colonies were obtained, and expression of MafB in myeloblasts directed their dierentiation to macrophages . Similarly, expression of c-Maf in HL-60 or U937 cells led to monocytic dierentiation (Hegde et al., 1999) . cMaf can interact with c-Myb, interfering with its activation of early myeloid genes; however, interference with c-Myb activities was not sucient to induce monocytic dierentiation in HL-60 cells (Hegde et al., 1998 (Hegde et al., , 1999 .
Egr-1 and WT1
Egr-1 is a member of a family of zinc-®nger transcription factors which binds the consensus 5'-GCGGGGCG-3' (Crosby et al., 1991) . The DNAbinding domain of WT1 isoforms lacking a KTS insert is strongly homologous, and these WT1 isoforms bind the same consensus site (Rauscher et al., 1990) . Egr-1 is expressed in multiple tissue including the terminal stages of macrophage and neutrophil dierentiation (Nguyen et al., 1993; Krishnaraju et al., 1995) . Egr-1 is necessary for monocytic dierentiation of U937 or M1 cells, prevents the granulocytic dierentiation of HL-60 or 32D cl3 cells, induces the macrophage dierentiation of M1 cells in the absence of IL-6 and endows 32D cl3 cells with the potential to dierentiation to macrophages in response to GM-CSF (Nguyen et al., 1993; Krishnaraju et al., 1995 Krishnaraju et al., , 1998 . In addition, ectopic expression of Egr-1 in myeloid marrow progenitors increased the proportion of CFU-M at the expense of CFU-G and, to a lesser extent, BFU-E (Krishnaraju et al., 2001) . Mice lacking Egr-1 develop normal numbers of macrophages, perhaps due to compensatory eects from other Egr family members . As Egr-1 is induced rapidly by phorbol esters even in the absence of protein synthesis, Egr-1 may be an important target of M-CSF receptor signaling (Nguyen et al., 1993) .
Several WT1 isoforms are expressed as a result of alternative splicing. The transcriptional regulatory domain of WT1 is aected by the presence or absence of exon 5 and its DNA-binding domain is aected by the presence or absence of a three amino acid sequence, KTS (Haber et al., 1991) . The presence of the KTS insert alters the DNA-binding speci®city of WT1 (Drummond et al., 1994) . Lack of WT1 is lethal at or before birth, and results in urogenital defects and lack of spleen development (Kreidberg et al., 1993; Herzer et al., 1999) . Marrow development has not been characterized in these mice. Expression of WT1 isoforms containing the KTS insert induces monocytic dierentiation of M1 cells, whereas isoforms lacking this insert, and so mimicking Egr-1 DNA-binding speci®city, prompt a G1 arrest (Smith et al., 1998) . In contrast, WT1(7KTS) accelerates whereas WT1(+KTS) blocks 32D cl3 granulocytic dierentiation in response to G-CSF (Inoue et al., 1998; . Inhibition of monocyte development by WT1(7KTS) may re¯ect dominant inhibition of Egr-1, via competition for DNA-binding. In addition, acceleration of granulocytic dierentiation by WT1(7KTS) may re¯ect limitation of G1 progression via direct repression of the cyclin E promoter . WT1 is normally expressed in immature, CD34+ marrow cells and is down-regulated in response to stem cell factor and G-CSF (Maurer et al., 1997) . The expression of speci®c WT1 isoforms in marrow progenitors remains to be determined. Perhaps WT1(7KTS) serves to interfere with monocyte development and WT1(+KTS) serves to interfere with granulocytic development.
Retinoic acid receptors
Retinoic acid receptors a, b, g(RARa, RARb, and RARg) bind DNA via their zinc-®nger domains as heterodimers with RXR proteins. RARs are broadly expressed, with RARa being preferentially expressed in myeloid cells (de The et al., 1989) . The DNA consensus for RAR-RXR DNA-binding is a direct repeat of 5'-(A/G)G(G/T)TCA-3' separated by 2 ± 5 bps (Umesano et al., 1991; Naar et al., 1991) . Dominant-inhibition of RARa arrests granulocytic dierentiation at the promyelocyte stage (Tsai and Collins, 1993) . Mice lacking RARa1 or RARg have normal myeloid development, whereas while mice lacking both of these RAR isoforms have normal myeloid progenitor numbers, their neutrophilic dierentiation arrests at the myelocyte stage (Labrecque et al., 1998) . This phenotype is similar to that observed in C/EBPe (7/ 7) mice, and RARa directly activates the C/EBPe promoter (Yamanaka et al., 1997; Chih et al., 1997) . While regulation of the C/EBPe promoter by RARs may account for the requirement of RARs for terminal granulopoiesis, it remains to be established that regulation of RAR activities plays a role in normal hematopoiesis.
CCAAT displacement protein (CDP) and HoxA10
CDP is a widely expressed protein that represses gene expression, at least in part, via competition for transactivator binding to DNA elements which loosely ®t the 5'-CCAAT-3' motif (Barberis et al., 1987; Luo and Skalnik, 1996) . Decreased CDP DNA-binding during the terminal stages of granulopoiesis combined with its ability to repress the gp91-phox promoter led to the proposal that inactivation and/or decreased expression of CDP is required for terminal neutrophil maturation (Skalnik et al., 1991) . The mechanism whereby CDP DNA-binding becomes inactivated during granulopoiesis remains to be elucidated. 32D cl3 cells overexpressing CDP do not express C/EBPe in response to G-CSF, and the human C/EBPe promoter contains a binding site for CDP at 71472 bp which potentially accounts for the reduced activity of an 1800 bp compared to a 726 bp promoter fragment in 32Dwt18 cells (Khanna-Gupta et al., 2001) . Inhibition of C/EBPe expression may account for the combined loss of LF, neutrophil collagenase, and neutrophil gelatinase in 32D cells expressing exogenous CDP (Lawson et al., 1998) . However, a role for CDP in regulating granulopoiesis in normal cells remains to be con®rmed.
HoxA10 is a homeobox protein which binds preferentially to 5'-TTAT-3' as a heterodimer with PBX (Chang et al., 1996) . The ability of HoxA10 to repress the gp91-phox promoter led to the suggestion that HoxA10 plays a role analogous to CDP during granulopoiesis (Eklund et al., 2000) . HoxA10 is highly expressed in CD34+ and is only weakly detected in CD347 marrow cells and is not present in mature neutrophils or monocytes (Sauvageau et al., 1994; Lawrence et al., 1995) . HoxA10 is preferentially expressed in myeloid cell lines, HoxA10 (7/7) mice have increased numbers of granulocytes, and over-expression of HoxA10 inhibits monocytic colony formation in vitro and produces AML in vivo (Lawrence et al., 1995; Zhang et al., 1996b; Thorsteinsdottir et al., 1997) . Overall, as HoxA10 expression is apparently lost prior to CDP activity, it may play a role in maintaining an earlier stage in myelopoiesis. While HoxA10 can activate the p21 WAF1/Cip1 promoter in U937 cells, it is tempting to speculate that HoxA10 in fact represses this promoter in immature myeloid cells, enabling cell proliferation and thereby inhibiting terminal dierentiation (Bromleigh and Freedman, 2000). As we have discussed, other Hox proteins may play a role in regulating myelopoiesis as well .
Like CDP, Sp1 is found in multiple tissues, but Sp1 is expressed at particularly high levels in maturing granulocytes (Saer et al., 1991) . This expression pattern combined with the ®nding that Sp1 regulates several granulocytic and monocytic genes via its consensus-binding site, 5'-GGGCGG-3', raises the possibility that Sp1 plays a role in regulating terminal myelopoiesis.
Myeloid zinc finger 1 (MZF-1)
MZF-1 was isolated as a zinc ®nger protein preferentially expressed in myeloid cell lines . MZF-1 is preferentially expressed in immature myeloid cells, and reduction of its expression inhibits the formation of CFU-G (Bavisotto et al., 1991) . The two zinc ®nger clusters within MZF-1 bind the consensus sites 5'-AGTGGGGA-3' and 5'-CGGGnGAGGGGGAA-3' (Morris et al., 1994) . The MPO and LF promoters contain bindings sites capable of interacting with both sets of zinc ®ngers, and the CD34 promoter contains two such sites located at about 7500 bp. MZF-1 activates the CD34 promoter via these sites in hematopoietic cell lines (Morris et al., 1995) . MZF-1 (7/7) mice develop normal blood cells, but develop a progressive increase in monocytic cells followed by the late formation of an in®ltrating monocytic leukemia. In addition, a much greater proportion of MZF-1 (7/7) myeloid and erythroid progenitors are in cell cycle without increased expression of c-Myb (Gaboli et al., 2001) . This phenotype may not have been detected during antisense inhibition of MZF-1 in CFU-G due to residual expression (Bavisotto et al., 1991) . p53, retinoblastoma protein (Rb), STAT3, and BLIMP-1 When induced by DNA strand breaks, p53 activates pathways leading to apoptosis or cell cycle arrest (Canman et al., 1995) . p53 is detected at low levels in mature myeloid and lymphoid cells and p53 levels increase in ML-1 cells as they dierentiate to monocytes in response to phorbol esters (Kastan et al., 1991) . As c-Jun represses the p53 gene, this eect of phorbol esters is likely indirect, perhaps via PKC activation or cell cycle arrest (Schreiber et al., 1999) . Exogenous p53 prompts monocytic dierentiation in U937 cells or in 32D cl3 cells also expressing v-src or an activated M-CSF receptor, without inducing G1 arrest or apoptosis (Soddu et al., 1996; Martinelli et al., 1997; Ehinger et al., 1998) . The induction of monocytic dierentiation in 32D cl3 cells is striking, given their propensity for granulocytic maturation. Induction of U937 cell dierentiation by p53 depended upon the integrity of its trans-activating domain and was not inhibited by bcl-2 (Chylicki et al., 2000) . Although mice lacking p53 develop normally, the p53-related protein, p73, potentially compensates for p53 de®ciency as p73 is expressed in immature but not terminally dierentiated myeloid cells (Lowe et al., 1993; Peters et al., 1999) .
Rb cooperates with E2F family members to repress genes required for S phase entry (Weinberg, 1995) . Rb is down-regulated during granulopoiesis but is upregulated during monocyte development (Bergh et al., 1999) . Consistent with this expression pattern, antisense inhibition of Rb expression in marrow progenitors reduced CFU-M in favor of CFU-G (Bergh et al., 1999) . Perhaps complexes which form between hypophosphorylated Rb and either C/EBPb or PU.1 are essential for monocyte maturation (Hagemeier et al., 1993; Chen et al., 1996) . Rb (7/7) mice are embryonic lethal and have increased erythroblasts, whereas lack of the Rb-related protein p107 leads to myeloid hyperplasia (Lee et al., 1992; Lecouter et al., 1998) . As with p53, Rb family members may compensate for each other in knockout mice to help mediate myelopoiesis.
Dominant inhibition of STAT3 in 32D cl3 cells allows expression of early markers but prevents cell cycle arrest and induction of late markers, although C/ EBPe induction was not prevented (Shimozaki et al., 1997; Nakajima and Ihle, 2001 ). These ®ndings suggest that STAT3 is required for induction of G1 cell cycle arrest during granulopoiesis. Consistent with this model, dominant inhibition of STAT3 prevents p27
Kip1 induction by G-CSF in 32D cl3 cells, and the p27 Kip1 promoter is activated directly by STAT3 (De Koning et al., 2000) .
BLIMP-1 is a zinc-®nger DNA-binding protein which may contribute to terminal myeloid and Blymphoid dierentiation at least in part by repressing transcription of the c-myc gene (Chang et al., 2000) .
Lineage commitment and progression
The widespread role of C/EBPs and PU.1 in regulating myeloid genes combined with the defects evident in C/ EBPa (7/7) and PU.1 (7/7) mice make these transcription factors leading candidates for roles in determining the myeloid lineages. As PU.1 (7/7) mice lack B cells and monocytes and have greatly reduced numbers of neutrophils, whereas C/EBPa (7/7) mice only lack maturing granulocytes, it would seem reasonable to place PU.1`upstream' of C/EBPs in this regard. Further support for this idea comes from the ®nding that PU.1 and GATA-1 inhibit each others activities, suggesting their relative importance in the myeloid versus the erythrod/megakaryocyte lineages. However, several lines of evidence suggest that C/EBPs might play a role in specifying the bipotent granulocyte-monocyte progenitor (GMP): C/EBP-mediated down-regulation of FOG RNA is essential for eosinophil development, and perhaps is also required for GMP formation (Querfurth et al., 2000) . Second, fractionation studies suggest that pluripotent stem cells ®rst commit to a common lymphoid progenitor (CLP) and a common myeloid progenitor (CMP) and that Bcells and macrophages develop from the CLP and the CMP respectively ; in this model, it is dicult to draw a 1 : 1 correspondence between PU.1 and a speci®c progenitor. Third, the CMP gives rise to the GMP, the megakaryocyte-erythroid progenitor (MEP), and perhaps an eosinophilic progenitor (EoP), and evidence has been presented indicating that high-level GATA-1 speci®es the MEP whereas the combination of a C/EBP and lower levels of GATA-1 speci®c to the eosinophil lineage (Kulessa et al., 1995; McDevitt et al., 1997; Yamaguchi et al., 1999) . Therefore, if the third branch eminating from the CMP, the GMP, were determined by the expression of C/EBP without GATA-1, then the tripartite decision of the CMP would depend on only two factors ± such simplicity is attractive. And fourth, higher levels of PU.1 are present in and are required for the monocyte lineage, compared to the B-lineage (DeKoter and Singh, 2000) , and as C/EBPa rapidly induces PU.1 RNA expression in 32D cl3 and Ba/F3 cells, it might do so in the GMP as well (Wang et al., 1999) . One dicult with this alternative is that C/EBP would be expected to induce PU.1 in eosinophils, which would inhibit GATA-1 activity. PU.1 is present in mature eosinophils, and PU.1 RNA is strongly upregulated when human CD34+ cells dierentiate to eosinophils in response to IL-5 (J Du and SJ Ackerman, personal communication). PU.1 7/7 mice have greatly reduced numbers of mature eosinophils, and direct evidence for the regulation of an eosinophil-speci®c gene by PU.1 has been presented (Du et al., 1998; van Dijk et al., 1998) . Perhaps, partial inhibition of GATA-1 by PU.1 in fact serves to direct CMPs to the EoP, as opposed to the MEP. Figure 1 illustrates two alternatives for the speci®cation of the GMP, by high levels of PU.1 alone or by high levels of PU.1 achieved via expression of C/ EBPs, likely including C/EBPa as this isoform is expressed most prominently in immature hematopoietic cells (Scott et al., 1992; Radomska et al., 1998) . Detailed discussions of erythroid and lymphoid lineage development are presented elsewhere in this issue ± of note however is the ®nding that Pax5 suppresses GM-CSF Receptor RNA expression, again demonstrating the role of negative cross-talk between hematopoietic lineages (Chiang and Monroe, 2001 ). Both C/EBPdependent and -independent commitment from the CMP to the GMP might occur, with requisite elevation of PU.1 levels. Our ®nding that either C/EBPa-ER or G-CSF receptor signals, acting in the presence of a dominant-inhibitory C/EBP, elevate PU.1 RNA in 32D cl3 cells is consistent with this idea (Wang et al., 1999; Wang and Friedman, 2002) .
The issue of granulocyte versus monocytic lineage choice also must be resolved. The ®ndings that Jun and Maf family members can each induce the monocyte lineage in cell lines and that these proteins both interact with AP-1 consensus sites leads to the speculation that Maf:Maf, Maf:Jun, Maf:Fos, Jun:Jun, or Jun:Fos dimers initiate monopoiesis in conjunction with PU.1. The continued presence of C/EBPs, to maintain elevated PU.1 levels, may be required as well. In the absence of Maf or Jun proteins, C/EBPs and PU.1 may specify the granulocyte lineage. The ®nding that increased levels of C/EBPa favor granulocytic over monocytic dierentiation in U937 cells suggests that, as with PU.1 and GATA-1, C/EBP levels may play a role in lineage commitment decisions (Radomska et al., 1998) . A model for granulocyte versus monocyte lineage determination is illustrated in Figure 1 .
Egr-1 may serve to simultaneously enable monocyte lineage progression and to prevent cross-over to neutrophil development. Granulocyte lineage progression requires C/EBPe, which may be induced by C/ EBPa and/or RARs. Loss of CDP DNA-binding is also required for terminal granulopoiesis. In addition, progression to neutrophils and macrophages is associated with cell cycle arrest, elevating hypo-phosphory- Figure 1 A model for transcriptional regulation of granulocyte and monocyte lineage commitment and progression. Detailed discussions of lymphoid and erythroid lineage determination are presented elsewhere in this issue. Pluripotent hematopoietic stem cells (HSC) are directed to the CLP in part by Ikaros, T cell development required GATA-3, and B-cell development requires Pax5 and low levels of PU.1. The speci®cation of the CMP from the HSC remains obscure ± perhaps this is a default pathway in the absence of Ikaros. Development of the MEP requires high-level GATA-1, whereas the development of the eosinophil lineage requires lower level (or lower activity) of GATA-1 along with a C/EBP. PU.1 induced by C/EBPs may in fact serve to reduce GATA-1 activity in this lineage. High-level GATA-1 may further direct the MEP along the erythroid lineage (E), NF-E2, FOG, and GATA-1 may specify megakaryocyte progenitors (Meg), and MITF in combination with GATA-1 or GATA-2 may allow basophilic progenitors to form (Baso). Development of the GMP requires high level PU.1 expression, which may develop through both C/EBP-dependent and C/EBP-independent mechanisms. Redundancy with respect to DNA-binding and trans-activation potency might allow one or more C/EBP family members to play a role in this regard. Maf and/or Jun family members may then direct the GMP towards a committed monocyte progenitor, and increased levels of C/EBPs may specify the neutrophil progenitor. Monocyte lineage progression depends upon the continued presence of PU.1 and perhaps C/EBPs, and may require Egr-1, which could also serve to repress the granulocytic program. ICSBP may be an important PU.1 co-factor during monocyte maturation. Terminal maturation may in addition depend upon increased expression of hypo-phosphorylated Rb and/or p53 as a consequence of cell cycle arrest. Granulocyte maturation requires PU.1, C/EBPs, RARs, C/EBPe, and Sp1 and may also require inactivation of CDP DNA-binding. RARs, C/EBPa, and/or decreasing CDP activities may in fact serve to induce C/EBPe lated Rb and p53. These proteins may participate in terminal dierentiation, as best shown for monopoiesis. And cell cycle arrest may inactivate factors such as CBF and c-Myb which participate in early stages of dierentiation. A model of myeloid lineage progression is shown in Figure 1 .
Perspectives for the future
Many questions remain unanswered regarding the transcriptional regulation of granulocyte and monocyte development. With respect to the cellular basis for initiating these lineages: What are the relative contributions of granulocyte/monocyte and B-cell/monocyte progenitors to mature blood elements; do some granulocyte or monocyte progenitors develop directly from pluripotent stem cells; how irreversible are commitment decisions? With respect to gene regulation: Are there additional important transcriptional regulators of myeloid genes remaining to be uncovered via detailed investigation of promoters and distal enhancers; are there lineage-restricted co-activators or co-repressors which participate in lineage speci®cation? With respect to key transcription factors, further clari®cation of the regulatory network illustrated in Figure 1 is needed: Which factor or factors specify each lineage and at what levels of expression; can family members act redundantly in this regard; what additional cooperative mechanisms operate among transcriptional regulators; what roles do cytokine receptor signaling and transcription factor modi®ca-tions play in each commitment decision and in each step of lineage progression? The answers to these questions will provide general lessons in developmental biology and insights into leukemogenesis and will enable applications in clinical hematology, oncology, and gene therapy.
